NCT02280434View on ClinicalTrials.gov

Phase 1 Study Accessing the Safety and Tolerability of CBP-307

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Autoimmune Diseases
Interventions
DRUG

CBP-307

DRUG

Placebo

Trial Locations (1)

3004

Nucleus Network, Melbourne

Sponsors

Collaborators (1)

Nucleus Network Ltd
All Listed Sponsors
collaborator

Tigermed Consulting Co., Ltd

INDUSTRY

collaborator

Nucleus Network Ltd

OTHER

lead

Connect Biopharm LLC

INDUSTRY